Managed care
Michael Komin MD Medical Corportion
Michael Komin MD Medical Corportion was paid $6.08M by Medicaid between Jan 2018 and Jul 2024, across 80 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 64% of everything it billed.
33Billing provider infoMICHAEL KOMIN MD MEDICAL CORPORTION
SHAFTER, CA 93263
SHAFTER, CA 93263
33aNPI1164696449assigned 04/17/2008
33bProvider typePreferred Provider Organization
28Total paid$6.08M
24GClaims219,604
24DCodes billed80
24AFirst – last monthJan 2018 – Jul 2024
Compared with peers
Next to other Preferred Provider Organization providers in California
Rank by total paid#3 of 100
Median peer was paid$80K
This provider vs. median76×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,219 | $645K | |
| 2019 | 23,691 | $833K | |
| 2020 | 34,362 | $1.04M | |
| 2021 | 50,118 | $1.23M | |
| 2022 | 42,973 | $1.00M | |
| 2023 | 42,190 | $887K | |
| 2024incomplete | 10,051 | $437K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 64% | 55,637 | 43,207 | $3.87M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 28,984 | 19,096 | $716K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 34,524 | 20,590 | $697K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 3.2% | 5,458 | 1,988 | $197K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.0% | 9,466 | 5,636 | $123K |
| G0467 | Community health center visit, returning patientFederally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 1.4% | 2,709 | 1,954 | $88K |
| 98940 | <1% | 5,093 | 2,126 | $55K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,819 | 3,697 | $43K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 481 | 394 | $42K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,619 | 3,270 | $30K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,567 | 2,485 | $25K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | <1% | 666 | 350 | $23K |
68 more codes
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 2,685 | $15K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 190 | $15K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,412 | $14K |
| 96127 | <1% | 4,261 | $13K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 384 | $13K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 274 | $13K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 641 | $11K |
| 90674 | <1% | 495 | $10K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 182 | $9K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 226 | $8K |
| 82962 | <1% | 4,097 | $5K | |
| 99385 | <1% | 72 | $5K | |
| 87428 | <1% | 116 | $5K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 108 | $4K |
| 80305 | <1% | 655 | $3K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 173 | $3K |
| 97012 | <1% | 417 | $3K | |
| 81002 | <1% | 2,850 | $3K | |
| 83986 | <1% | 983 | $2K | |
| 82271 | <1% | 1,074 | $2K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 50 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 438 | $2K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 182 | $2K |
| 20610 | <1% | 36 | $1K | |
| 93000 | <1% | 89 | $1K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 60 | $1K |
| 90700 | <1% | 158 | $933.75 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 52 | $587.73 |
| 97014 | <1% | 86 | $529.34 | |
| 90658 | <1% | 21 | $431.45 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 116 | $365.48 |
| 90670 | <1% | 69 | $348.75 | |
| 90713 | <1% | 62 | $292.50 | |
| 88150 | <1% | 51 | $287.50 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 122 | $232.78 |
| 90648 | <1% | 49 | $225.00 | |
| 90734 | <1% | 25 | $135.00 | |
| 1159F | <1% | 55 | $57.51 | |
| 3044F | <1% | 396 | $37.01 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 530 | $36.00 |
| 1160F | <1% | 42 | $22.99 | |
| 94760 | <1% | 393 | $19.57 | |
| 3074F | <1% | 10,492 | $10.21 | |
| 3078F | <1% | 9,269 | $10.21 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 420 | $6.72 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 50 | $6.00 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 20 | $0.20 |
| 3080F | 0% | 853 | $0.00 | |
| 4050F | 0% | 199 | $0.00 | |
| 1000F | 0% | 4,062 | $0.00 | |
| 97802 | 0% | 13 | $0.00 | |
| Z71.8 | 0% | 47 | $0.00 | |
| 3075F | 0% | 2,453 | $0.00 | |
| 3079F | 0% | 4,917 | $0.00 | |
| 2000F | 0% | 1,607 | $0.00 | |
| 3351F | 0% | 782 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 31 | $0.00 |
| 90899 | 0% | 13 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 113 | $0.00 |
| Z71.3 | 0% | 48 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 12 | $0.00 |
| 4019F | 0% | 214 | $0.00 | |
| 90461 | 0% | 333 | $0.00 | |
| 3077F | 0% | 2,052 | $0.00 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 83 | $0.00 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 55 | $0.00 |
| A4617 | Mouth piece | 0% | 49 | $0.00 |
| 3046F | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKOMIN, MICHAEL (DOCTOR)